AstraZeneca Pharma India slipped 1.07% to Rs 3,370 after the company's standalone net profit dropped 45.03% to Rs 10.24 crore on 9.38% decline in net sales to Rs 175.40 crore in Q1 June 2021 (Q1 FY22) over Q1 June 2020 (Q1 FY21).
Standalone profit before tax tumbled 48.82% to Rs 13.50 crore in Q1 FY22 as against Rs 26.38 crore in Q1 FY21. The Q1 result was declared during market hours today, 9 August 2021.
Meanwhile, the board has declared an interim dividend of Rs 2 per equity share for the financial year 2021-22. It has fixed 20 August 2021 as the record date for determining the entitlement of the shareholders for the payment of interim dividend.
AstraZeneca Pharma India is a listed subsidiary of AstraZeneca Plc, UK. The company has an innovative portfolio in crucial areas of healthcare including cardiovascular, renal & metabolic diseases, oncology and respiratory.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU